Close Menu

360Dx

Quest and LabCorp recently highlighted increased compensation costs while other industry observers have seen salaries rising for specialties like molecular.

The company's Curian immunoassay instrument is currently in front of the FDA, and the PediaStat will likely be submitted later this year.

The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.

The program aims to consent up to 150,000 patients to a larger biobank program and return selective preemptive PGx results through their medical center physicians.